Trial Profile
Creating Metabolic Vulnerabilities in Patients With EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR With Osimertinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Fludeoxyglucose F-18
- Indications Glioblastoma
- Focus Therapeutic Use
- 01 Dec 2023 Planned End Date changed from 1 Nov 2024 to 1 Oct 2025.
- 01 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Oct 2024.
- 25 Jan 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.